Gregory Weinhoff MD MBA

Chief Financial Officer

Dr. Gregory Weinhoff, MD, MBA, is Chief Financial Officer of Centessa Pharmaceuticals. Most recently, Greg was a Co-Founder and Chief Financial and Chief Business Officer at Arvelle Therapeutics B.V. In that role, he was responsible for sourcing cenobamate, a novel anti-seizure medicine with best-in-class efficacy, negotiating the license with SK Biopharmaceuticals for European rights, and raising a $207.8M start-up financing which was one of the largest start-up financings for a European biopharma. Greg played a key role in preparing the Arvelle organization for commercialization and driving the strategic sale process which resulted in the $960M acquisition by Angelini Pharma.

Previously, Greg was Chief Financial Officer at Axovant Sciences, Inc., where he oversaw Finance, Accounting, Investor Relations and Business Development. At Axovant, he was the Principal Financial and Accounting Officer for SEC purposes and was responsible for three public financings, a private placement, and a venture debt financing.

Before becoming Chief Financial Officer of Axovant, Greg spent fifteen years as an early-stage healthcare venture capitalist at CHL Medical Partners. He was the founding Chief Executive Officer and sole Series A investor in Amicus Therapeutics where he remained a Board member and member of the Audit Committee through its IPO in 2009. Prior to graduate school, Greg was a financial analyst in Morgan Stanley & Co.’s healthcare corporate finance group.

Greg holds an MD from Harvard Medical School, an MBA from Harvard Business School, and an AB in Economics from Harvard College.

Scroll to Top
pipeline chart header registrational white

SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence

Hemophilia B